Clinical Trials Logo

Disease clinical trials

View clinical trials related to Disease.

Filter by:

NCT ID: NCT00652600 Completed - Clinical trials for To Determine Bioequivalence Under Fed Conditions

Bioavailability Study of Propranolol Under Fed Conditions

Start date: September 2005
Phase: Phase 1
Study type: Interventional

To compare the single-dose bioavailability of Propranolol 160 Mg ER Capsules with Inderal-La

NCT ID: NCT00650611 Completed - Schizophrenia Clinical Trials

A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic Disorders

Start date: December 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of oral ziprasidone in children and teens with psychotic disorders

NCT ID: NCT00646464 Completed - Clinical trials for Attention Deficit Hyperactivity Disorder

New Continuous Performance Tests (CPT) for the Diagnosis of Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)

CPT
Start date: February 2008
Phase: N/A
Study type: Observational

Computerized continuous performance tests (CPT) considered the "gold standard" for diagnosis of Attention Deficit/Hyperactivity Disorder (ADHD. This type of tests are based mainly on visual performance. The available tests suffer from high false negative errors. This raises questions regarding their ability to correctly diagnose ADHD. With the expanding knowledge regarding the neurobiological basis in ADHD we have learned that attention is not a general property of the whole brain, but involves several coordinated networks. This knowledge promoted us to the stage in which we can recognize different types of attention domains. Our diagnosis test can separate between the different attention abilities and provide specific diagnosis. Our program is individually fits for the specific child difficulties and covers a wider range of needs. So, it can be helpful to a larger variety of children with different needs.

NCT ID: NCT00645944 Completed - Schizophrenia Clinical Trials

Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia

Start date: April 2008
Phase: N/A
Study type: Interventional

The major goal of this project is to investigate established insomnia treatments in a schizophrenia population to see if the improved sleep leads to overall better quality of life. In addition, we hypothesize that the insomnia treatment may also lead to observed improvements in other symptoms associated with schizophrenia such as cognitive impairments, obesity, and negative symptoms.

NCT ID: NCT00644358 Completed - Clinical trials for Major Depressive Disorder

A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)

Start date: December 31, 2007
Phase: Phase 3
Study type: Interventional

This open label 52-week clinical trial is designed to assess the safety and tolerability of vilazodone and to analyze genetic markers of response to vilazodone in adult patients diagnosed with MDD. This study will enroll approximately 600 patients.

NCT ID: NCT00641303 Completed - Breast Cancer Clinical Trials

Acupuncture in Reducing Muscle and Bone Symptoms in Women Receiving Letrozole, Exemestane, or Anastrozole for Stage 0, Stage I, Stage II, or Stage III Breast Cancer

Start date: May 2008
Phase: N/A
Study type: Interventional

RATIONALE: Acupuncture may help relieve muscle and bone pain caused by aromatase inhibitor therapy, such as letrozole, exemestane, and anastrozole. PURPOSE: This randomized phase II trial is studying acupuncture to see how well it works in reducing muscle and bone symptoms in women receiving letrozole, exemestane, or anastrozole for stage 0, stage I, stage II, or stage III breast cancer.

NCT ID: NCT00636909 Completed - MULTIPLE MYELOMA Clinical Trials

Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders

MINI HEME
Start date: July 1999
Phase: Phase 2
Study type: Interventional

The purpose of this study is to provide allogeneic stem cell transplantation to patients who have not traditionally undergone this procedure because of it high incidence of treatment related side effects. We hope to decrease these side effects by decreasing the chemotherapy dose prior to transplant (non-myeloablative, smaller dose of chemotherapy given so bone marrow is not completely eliminated) and by using donated stem cells to treat cancer of the blood.

NCT ID: NCT00635921 Completed - Clinical trials for Borderline Personality Disorder

Ziprasidone in the Treatment of Borderline Personality Disorder

Start date: March 2004
Phase: Phase 2
Study type: Interventional

Objective: The aim of this double-blind, placebo-controlled study was to evaluate the efficacy and tolerability of ziprasidone in the treatment of adult patients with Borderline Personality Disorder (BPD). Method: Sixty BPD patients were included in a 12-week, single-center, double-blind, placebo-controlled study. The subjects were randomly assigned to ziprasidone or placebo in a 1:1 ratio following a two-week baseline period. The Clinical Global Impression scale for use in BPD patients (CGI-BPD) was the primary outcome measure, and other scales and self-reports related to affect, behavior, psychosis, general psychopathology domains and clinical safety were included.

NCT ID: NCT00631657 Completed - Mental Disorders Clinical Trials

A 6-Month Efficacy and Safety Study of Org 50081 in Adult Patients With Chronic Primary Insomnia (21106/P05701/MK-8265-002)

Start date: March 4, 2008
Phase: Phase 3
Study type: Interventional

To investigate the long-term efficacy and safety of treatment with esmirtazapine (Org 50081, SCH 900265, MK-8265) compared to placebo, in participants with chronic primary insomnia. Primary efficacy variable is Total Sleep Time (TST).

NCT ID: NCT00626236 Completed - Clinical trials for Attention Deficit Disorder With Hyperactivity

Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems

Start date: September 2008
Phase: Phase 2
Study type: Interventional

It is hypothesized that, when given at the lowest effective dose, the favorable side effect profile combined with it's lower propensity for weight gain would make SPN-810 a candidate for treatment of persistent serious conduct problems in pediatric subjects with ADHD.